Importantly, the HRR abnormalities are observed in 31% of advanced prostate cancers and include: BRCA2 (9.8%), CDK12 (5.6%), ATM (5.2%), CHEK2 (1.8%), BRCA1 (1.4%) FANCA (1.3%), and ATR (1.1%) [711]. This evidence concerns the gene CHEK2 and Familial prostate cancer.